Overview

The AVENIO ctDNA Surveillance Kit is a next-generation sequencing (NGS) liquid biopsy assay that’s specially designed and optimized to enable researchers to serial or longitudinal monitor tumor burden in Lung and Colorectal cancer over time. The Surveillance panel contains 197 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.

Features and Benefits of AVENIO ctDNA Surveillance Kit

  • Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Product Highlights

Detection of mutants with exceptional sensitivity and specificity2,3

  • >99% specificity for all classes of mutations
  • >99% positive predictive value (PPV) for  all classes of mutations

Profiling of a broad array of genes with a single assay kit

  • 17 assay targets in a single panel
  • 180 additional genes with frequently mutated regions
  • 471 frequently mutated regions associated with the presence of disease across 197 genes

View the list of 180 genes with select frequently mutated regions for longitudinal tumor burden monitoring in lung cancer and CRC using the AVENIO ctDNA Surveillance Kit.

A portfolio of NGS liquid biopsy assays  

The AVENIO ctDNA Targeted Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 77-gene AVENIO ctDNA Expanded Kit for profiling emerging and guideline-driven biomarkers.

References

1. National Comprehensive Cancer Network. October 15, 2016.

2. Newman AM, Lovejoy AF, Klass DM, et al., Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016; 34(5):547 – 555. doi:10.1038/nbt.3520.

3. Newman AM, Bratman SV, To J, et al., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548 – 554. doi:10.1038/nm.3519.

3. Data on file.